Anti-IL-2 receptor BT563 versus placebo: a randomized trial for induction therapy after liver transplantation.
Glanemann
M
M
Department of Surgery, Charité, Humboldt University, Berlin, Germany.
Langrehr
J M
JM
Raakow
R
R
Guckelberger
O
O
Lohmann
R
R
Klupp
J
J
Lobeck
H
H
Schlag
H
H
Keck
H
H
Bechstein
W O
WO
Settmacher
U
U
Neuhaus
P
P
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000276:immunology* / Q000401:mortality; D010919:Placebos; D011239:Prednisolone / Q000627:therapeutic use; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D015996:Survival Rate; D013997:Time Factors
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D010919:Placebos; D015375:Receptors, Interleukin-2; D016572:Cyclosporine; D011239:Prednisolone; C079843:inolimomab; D001379:Azathioprine